Överenskommelser har nåtts med majoriteten av obligationsinvesterarna.
Pharma Equity Group (“PEG” or “the Company”) presented a Q2-report characterized by further advancem...
Risk för lägre försäljning än vad marknaden estimerar, men marginalerna borde vara bättre än väntat.
Redeye concludes that the reported figures were overall stronger than we had forecasted.
Redeye sees the Q2 report coming in below estimates for both sales and EBIT.
Sales and profitability were weaker than expected; however, Redeye views this half-year period as be...
Organic growth of 66%, +14pp vs. ABGSCe ARPPU +11% vs.
Taaleri reported Q2 EBIT of EUR 4.4m, clearly above LSEG Data & Analytics consensus at EUR 3.
Transfer Group visade stark tillväxt under det andra kvartalet, med en nettoomsättning på cirka 51 (...
Slightly higher opex drives miss on EBIT EBIT (loss) -9% vs ABGSCe Estimates likley to be revised do...
Redeye provides an update following Nitro Games’ Q2 2024 report, which was solid across the board.
On 19 August 2024, Føroya Banki raised its 2024 net profit guidance range to DKK 250-280m (previousl...
Solid sequential improvements, first Ovzon 3 order '24e-'26e sales down 18-7% on softer orders than ...
Last Friday, management of Nepa presented the company’s quarterly report, which was followed by a Q&...
In terms of financials, Q2 was largely a repeat of Q1, with one-off replanting and remediation costs...
USA more stable, but poor result in Germany Negative EBIT revisions primarily driven by Germany Trad...
Administer’s Q2 EBITDA soared by 320% y/y, reaching EUR 1.
Exel’s Q2 was encouraging as EBIT recovered significantly after a challenging period of missing dema...
We expect flat sales for H2 with a decrease in domestic net sales due to non-recurring wholesale del...
Endomines' net sales for the first half of the year were roughly as expected, though profitability d...
